WO2004108635A2 - Mixed zeaxanthin ester concentrate and uses thereof - Google Patents
Mixed zeaxanthin ester concentrate and uses thereof Download PDFInfo
- Publication number
- WO2004108635A2 WO2004108635A2 PCT/US2004/015472 US2004015472W WO2004108635A2 WO 2004108635 A2 WO2004108635 A2 WO 2004108635A2 US 2004015472 W US2004015472 W US 2004015472W WO 2004108635 A2 WO2004108635 A2 WO 2004108635A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- zeaxanthin
- carotenoid
- esters
- composition according
- mixed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/179—Colouring agents, e.g. pigmenting or dyeing agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/40—Colouring or decolouring of foods
- A23L5/42—Addition of dyes or pigments, e.g. in combination with optical brighteners
- A23L5/43—Addition of dyes or pigments, e.g. in combination with optical brighteners using naturally occurring organic dyes or pigments, their artificial duplicates or their derivatives
- A23L5/44—Addition of dyes or pigments, e.g. in combination with optical brighteners using naturally occurring organic dyes or pigments, their artificial duplicates or their derivatives using carotenoids or xanthophylls
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B61/00—Dyes of natural origin prepared from natural sources, e.g. vegetable sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
- C12N15/825—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving pigment biosynthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Definitions
- Carotenoids have long been described as natural antioxidants that are known to quench free radicals before the free radicals attack healthy cells. More specifically, an antioxidant is a substance that significantly decreases the adverse effects of reactive species, such as reactive oxygen and nitrogen species, on the normal physiological function.
- reactive species such as reactive oxygen and nitrogen species
- Several highly oxidizing species are generated in biological systems, including singlet oxygen, hydroxyl radical, superoxide, hydrogen peroxide, organic hyperoxides and peroxyl radicals. These species can react with carotenoids by three distinctly different pathways: electron transfer, hydrogen abstraction, and radical addition [See Krinsky et al . , Annual Rev. Nutr. , 23:171-201 (2003) .]
- Zeaxanthin has been identified as a macular pigment of the retina and as having a functional role of protecting the retina against light-induced damage. Bernstein et al . , Exp . Eye Res . , 72(3) :215- 223 (2001) extracted carotenoids from ocular tissues
- RPE/choroid retina pigment epithelium/choroid
- HPLC high- performance liquid chromatography
- the predominant carotenoids of the macular pigment are lutein, zeaxanthin, and meso-zeaxanthin.
- the regular distribution pattern of these carotenoids within the human macula indicates that their deposition is actively controlled in this tissue.
- Increased macular carotenoid levels result from supplementation of humans with lutein and zeaxanthin.
- zeaxanthin predominates over lutein by a ratio greater than 2:1 in the foveal region, with the macular pigment optical density dropping by a factor of 100 and the zeaxanthin to lutein ratio reversing to about 1:2.
- zeaxanthin predominates over lutein by a ratio greater than 2:1 in the foveal region, with the macular pigment optical density dropping by a factor of 100 and the zeaxanthin to lutein ratio reversing to about 1:2.
- It has been suggested that some lutein is converted into the non-dietary meso- zeaxanthin primarily in the macula, by a mechanism that is less developed in infants than adults.
- Lycopene is naturally present as the red pigment in tomato skins, whereas ⁇ -carotene is the primary carotenoid pigment in carrots.
- U.S. Patent No. 5,618,988 teaches the preparation of carotenoid pigments such as ⁇ -carotene in storage organs of transformed plants such as carrots.
- U.S. Patent No. 5,858,700 teaches the isolation of lycopene crystals from an oleoresin as can be prepared from tomato skins. The structural formulas of lycopene and ⁇ -carotene are shown below.
- Astaxanthin a red xanthophyll whose structural formula is shown below, is widely used as a pigmenting agent for cultured fish and shellfish.
- Astaxanthin astaxanthin remain to be elucidated, but initial results suggest that it could play an important role in cancer and tumor prevention, as well as eliciting a positive response from the immune system. [See Tanaka et al . , Carcinogenesis 15(1):15-19 (1994), Jyonouchi et al . , Nutri tion and Cancer 19(3): 269-280 (1993) and Jyonouchi et al . , Nutri tion and Cancer 16(2) : 93-105 (1991) .]
- Carotenoids from food sources have lower bioavailability and absorption than diet supplementation with pure carotenoids.
- xanthophylls can be provided in ester or unesterified forms. Lutein bioavailability has been determined for lutein diester and unesterified lutein formulations as they might be incorporated into human dietary supplements. For most individuals studied, lutein provided by a particular lutein diester formulation was more bioavailable than was lutein provided by a formulation containing free lutein. The authors concluded that the lutein diester formulation posed no impediment to lutein bioavailability at the doses tested. A comparison with data from previous studies suggested that formulation dissolution was a greater limitation to bioavailability than lutein ester hydrolysis.
- the richest source of lutein found in nature is the marigold flower, Tagetes erecta, which typically contains 3 to 5 percent zeaxanthin esters.
- the Tagetes genus is a member of the family Composi tae, alternatively known as Asteraceae, and comprises some thirty species of strongly scented annual or perennial herbs. Tagetes are native from Arizona and New Mexico to Argentina.
- Cultivated species include Tagetes erecta, commonly referred to as African marigold, Tagetes patula, commonly referred to as French marigold, Tagetes erecta x patula, commonly referred to as Triploid marigolds, and Tagetes tenuifolia also known as Tagetes signata or signet marigold.
- a marigold inflorescence is a solitary head comprised of a dense cluster of several hundred sessile or subsessile small flowers also known as florets. Marigolds have radiate flower heads with outer ray florets that are ligulate or strap-shaped around the central tubular shaped disk florets. Some forms of marigold flower heads have most of their disk flowers transformed into ray flowers and contain few, if any, disk flowers. Such flower heads are referred to as double-flowered.
- the ray flowers or florets are often referred to as petals by lay persons who also refer to the flower heads as flowers .
- marigold flower heads will be referred to herein as flowers or flower heads, whereas the flower head-component flowers or florets, stamens, stigmas and carpels will be referred to as petals.
- the genus is recognized as a source for natural colorants, essential oils, and thiophenes .
- the carotenoids desired in poultry tissues are a function of their dietary concentration, because poultry do not have the ability to synthesize carotenoids de novo.
- Balnave et al . Asian-Australiasian J. Animal Sci . , 9(5) :515-517 (1996) .
- Xanthophyll marigolds differ in several characteristics from ornamental marigolds.
- xanthophyll marigolds are used as an extractable source for carotenoids and have plant habits that differ from ornamental marigolds.
- Ornamental marigolds typically grow only about 45 to about 60 cm from the ground, whereas xanthophyll marigolds grow to about.65 to about 70 cm from the ground.
- Xanthophyll marigolds grow in a bushier habit than do ornamental marigolds, and can be grown as row crops whereas ornamental marigolds typically cannot.
- Xanthophyll marigolds are typically dark orange in color, whereas ornamentals can be white, yellow, or orange in color, or can have mixed colors, including mahogany colors due to the presence of anthocyanin pigments.
- the pigmenting ability of marigold petal meal resides largely in the oxygenated carotenoid fraction known as the xanthophylls, primarily lutein esters.
- the xanthophyll zeaxanthin also found in marigold petals, has been shown to be effective as a broiler pigmenter, producing a highly acceptable yellow to yellow-orange color. [See Marusich et al . , Poul try Sci .
- Both ⁇ -carotene and ⁇ -carotene are understood to be formed by the action of appropriate cyclase enzymes on lycopene to first yield ⁇ -carotene or ⁇ -carotene that thereafter cyclize further to form ⁇ -carotene or ⁇ -carotene, respectively.
- Lycopene, ⁇ -carotene, ⁇ -carotene and ⁇ -carotene are each hydrocarbon carotenoids that are referred to in the art as carotenes.
- carotenoid pigments can be grouped into one or the other of two families: the hydrocarbon carotenes or the oxygenated xanthophylls.
- Phytoene the first C40 carotenoid in the pathway, is a colorless hydrocarbon.
- the hydrocarbon carotene pigments with the exception of ⁇ -carotene typically do not accumulate in marigold leaves or flower parts, whereas the xanthophylls do accumulate in both leaves and flower parts .
- FIG. 1 shows a schematic representation of the biological synthesis pathway for the production of lutein and zeaxanthin and later products from phytoene via lycopene, ⁇ -carotene, ⁇ -carotene and ⁇ -carotene.
- Lutein and zeaxanthin are present in marigold petals primarily as mono- and di-esters of fatty acids.
- FIG. 1 also notes epoxide-containing later products that can arise from zeaxanthin, of which violaxanthin is an intermediate in the abscisic acid biosynthetic pathway.
- 'Orangeade' is reported to contain xanthophylls at about 9-12 mg/g of dry whole flower heads (including calyx)
- 'Deep Orangeade' is reported to have about 10-13 mg/g of those pigments
- ' Scarletade ' is said to contain about 12-18 mg/g of xanthophyll pigments in dry flower heads weighed with the calyx.
- lutein is the major xanthophyll in marigold flowers
- some current varieties yield extract products with zeaxanthin ratios ⁇ [zeaxanthin/ (lutein + zeaxanthin) ] X 100% ⁇ typically in the 3 to 5 percent range (See Product Profile, Kemin Foods L.C., 600 E. Court Ave . Suite A, Des Moines, IA 50309) .
- zeaxanthin to lutein ratios obtained using 'Scarletade' are typically about 4 to about 7 percent, so that these flowers contain up to about 1.25 mg/g zeaxanthin or up to about 0.125 percent dry weight zeaxanthin.
- lutein esters from fresh marigold petals identified both monoesterified and diesterified lutein.
- the fatty acid distribution included palmitic, stearic, myristic, oleic, linoleic, lauric, and pentadecanoic [See Gomez et al . , Revista Espanola de Fisiologia 34:253-256 (1978) .]
- a study by Pogson et al . , Plant Cell , 8:1627-1639 (1996) used EMS to mutagenize plants of Arabidopsis thaliana . This detailed study of 4000 M 2 lines reported finding two loci in the carotenoid biosynthetic pathway in leaves that are involved with the production of lutein from ⁇ -carotene.
- lufcl lufc .
- lufcl lufc .
- lufcl lufc .
- lufcl lufc .
- a lycopene ⁇ -ring cyclase useful along with the lycopene ⁇ -ring cyclase for the preparation of ⁇ - carotene from lycopene .
- No teaching of the lycopene ⁇ -ring hydroxylase needed for lutein production is provided.
- Carotenoid biosynthesis is said in PCT application WO 00/32788 to be regulated by expression of a carotenoid synthesizing enzyme-encoding gene already present in marigolds such as those noted above, or by use of an anti-sense RNA encoded by such a nucleotide sequence provided. No evidence of such regulation is provided in the application.
- the phenomenon known as co-suppression by which the addition of a homologous gene causes both the native gene and transgene not to be expressed is not dealt with by those workers. [See for example, Fray et al., Plant Mol . Biol . , 22:589-692 (1993) or Finnegan et al., Bio/Technology, 12:883-888 (September 1994).]
- mutant marigold plants that provide flower petals containing a commercially useful amount of zeaxanthin esters.
- the plants have an altered ratio of lutein and zeaxanthin such that the usually reported 4 to about 7 percent zeaxanthin level is raised and the amount of lutein is decreased.
- the present invention contemplates a concentrated marigold plant extract that is preferably obtained from such a plant, and formulated to provide mixed zeaxanthin esters in an amount useful to prevent cancer, or to treat or prevent cataract formation, macular degeneration or a free radical-mediated disease.
- the present invention contemplates mixed zeaxanthin esters and more particularly a purified carotenoid concentrate comprising mixed zeaxanthin esters, as well as various mixed zeaxanthin ester compositions that can be prepared from that concentrate.
- a contemplated purified concentrate is a solid to semi-solid that includes mixed zeaxanthin esters at about 50 milligrams per gram or more of the concentrate with zeaxanthin at about 20 percent or more of the total carotenoids present when assayed after saponification.
- the zeaxanthin is about 25 percent or more of the total carotenoids present when assayed after saponification.
- the concentrate includes at least one additional carotenoid in free or esterified form.
- the mixed zeaxanthin esters are extracted from the species Tagetes erecta .
- Another aspect of the invention contemplates a diluted, purified carotenoid composition
- a diluted, purified carotenoid composition comprising mixed zeaxanthin esters dissolved or dispersed in a comestible diluent.
- a contemplated composition can be prepared using the above described concentrate and includes mixed zeaxanthin esters at about 10 milligrams per gram or more of the diluted composition with the zeaxanthin at about 20 percent or more of the total carotenoids present when assayed after saponification.
- the diluent is an oil.
- the composition is present encapsulated in a beadlet .
- the zeaxanthin is about 25 percent or more of the total carotenoids present when assayed after saponification.
- the composition includes at least one additional carotenoid in free or esterified form.
- the mixed zeaxanthin esters are extracted from the species Tagetes erecta .
- One contemplated use of this aspect of the invention is a nutritionally effective amount of the mixed zeaxanthin esters in a unit dosage form suitable for oral administration such as packets, tablets, capsules, and powders in vials or ampules.
- a nutritionally effective amount can be an amount that is sufficient to prevent cancer, or to treat or prevent cataract formation, macular degeneration or a free radical-mediated disease.
- the composition contains about 2 milligrams or more of mixed zeaxanthin esters .
- a diluted, purified carotenoid composition comprising mixed zeaxanthin esters dissolved or dispersed in a cosmetically acceptable diluent.
- a contemplated composition can be prepared using the previously described concentrate and includes mixed zeaxanthin esters at about 10 milligrams per gram or more of the diluted composition with the zeaxanthin at about 20 percent or more of the total carotenoids present when assayed after saponification.
- the zeaxanthin is about 25 percent or more of the total carotenoids present when assayed after saponification.
- the composition includes at least one additional carotenoid in free or esterified form.
- the mixed zeaxanthin esters are extracted from the ⁇ species Tagetes erecta .
- a contemplated use of this aspect of the invention includes a light protective amount of the mixed zeaxanthin esters contained in a cream, lotion, or ointment adapted for topical i application to human skin.
- the present invention has several benefits and advantages .
- One benefit of the invention is that large quantities of mixed zeaxanthin esters can now be economically provided in purified concentrated form.
- An advantage of the invention is that food supplements comprising a nutritionally effective amount of mixed zeaxanthin esters and an optional one or more carotenoid are now available.
- Another benefit of the invention is the provision of a food substance or beverage that contains a nutritionally effective amount of the mixed zeaxanthin esters .
- Yet a further benefit of the invention is the provision of a topical cream, lotion or ointment that contains a light protective amount of mixed zeaxanthin esters .
- FIG. 1 is a schematic representation of the biological synthesis pathway for the production of lutein and zeaxanthin in plants in which phytoene, the first C 0 carotenoid in the pathway, is converted in several steps (four arrows) through zeta-carotene ( ⁇ -carotene) to lycopene, after which the pathway splits to form ⁇ -carotene that contains one ⁇ -ring, then ⁇ -carotene that contains one ⁇ -ring and one ⁇ -ring or to form ⁇ -carotene that contains one ⁇ -ring , then ⁇ -carotene that contains two ⁇ -rings, and after several steps, to lutein or zeaxanthin, respectively, and the zeaxanthin branch continuing to the epoxide-containing xanthophylls antheraxanthin, violaxanthin and neoxanthin.
- ⁇ -carotene zeta-carotene
- zeaxanthin ratio is defined as the quantity of zeaxanthin present in a dried flower petal or leaf divided by the quantity of zeaxanthin plus lutein [zeaxanthin/ (lutein + zeaxanthin) ] present in that petal or leaf .
- zeaxanthin plus violaxanthin ratio is similarly calculated as the ratio of neoxanthin + violaxanthin divided by the sum of those two pigments plus lutein.
- ⁇ -carotene ratio the "lycopene ratio”, the “ ⁇ -cryptoxanthin ratio”, the "phytoene ratio” and the “phytofluene ratio” are similarly calculated using the named pigment amount as the sum of its isomers as the numerator and the sum of that pigment plus lutein as the denominator. The sums of appropriate percentages can also be used for those calculations.
- Those pigment quantities are determined by high performance liquid chromatography (HPLC) after saponification of a dried flower petal or leaf extract as discussed hereinafter so that the amount of each of lutein and zeaxanthin (or other pigment) is measured in the free compound form, e.g., alcohol form for lutein and zeaxanthin, present after saponification rather than in the esterified form that is present in the fresh flower petal, and chlorophyll that can be present in a leaf extract is destroyed.
- Some of the flower petals and leaves of plants discussed herein contain very low or unmeasurable amounts of lutein or lutein esters, e.g., less than about 0.1-0.2 percent.
- carotenes examples include phytoene, phytofluene, ⁇ -carotene, neurosporene , lycopene, ⁇ -carotene, ⁇ -carotene, ⁇ -carotene, and ⁇ -carotene.
- Xanthophyll examples include ⁇ -cryptoxanthin, lutein, ⁇ -crytoxanthin, zeaxanthin, antheraxanthin, violaxanthin, and neoxanthin.
- damage to be mitigated or prevented can be any skin damage such as burns, blisters, or damage appearing after chronic exposure to sun, e.g. premature aging of the skin.
- Exact amounts of protection vary depending upon the Sun Protection Factor (SPF) .
- SPF is a commonly used measure of photoprotection of a sunscreen.
- Sunscreen compositions comprising mixtures of molecules that absorb at different UV wavelengths and thereby protect the skin are known in the art. [See Haffey et al. U.S. Patent No. 5,087,445 and Turner et al . U.S. Patent No. 5,073,372.]
- the light protective amount of the mixed zeaxanthin esters is about 0.5 to about 20 percent weight of the topical cream, lotion, or ointment and more preferably 5 to 15 percent weight of the topical cream, lotion or ointment.
- Petals from the flowers of a plant of the family Composi tae, and in particular, a plant of the species Tagetes erecta, marigold are extracted commercially to supply lutein esters formulated into 10 percent beadlets and 15 percent oil suspensions. In those commercial formulations, zeaxanthin esters are a minor constituent. Analysis of a 15 percent lutein ester oil suspension, after hydrolysis, identified lutein at 75.7 milligrams per gram, zeaxanthin at 3.9 milligrams per gram and crytoxanthin at 0.4 milligrams per gram. [See Cognis Corp. web site at cognis.com] .
- a marigold having an altered carotenoid profile can be used to provide the mixed zeaxanthin esters in a concentrate or diluted compositions.
- Plants having altered carotenoid profiles can be produced through various methods of mutagenesis or by genetic engineering to form a transgenic plant as is disclosed in the before-noted co-owned patent applications.
- samples were selected having lutein peak areas greater than 1565 and/or zeaxanthin peak areas greater than 91. Samples were also selected only for high lutein peak area, and for zeaxanthin ratios greater than 10 percent. A total of 88 mutants were identified from 21,754 assayed samples using these selection parameters. The total number of mutants resulting from each EMS seed treatment is shown in Table 2, below.
- the treated seeds identified as M x seeds, were then sown in trays containing soilless potting mix. After three to four weeks, the seedlings were transplanted into the field. Flowers produced by these plants were bagged to prevent cross- pollination, and were permitted to spontaneously self-pollinate.
- the resulting seeds identified as M 2 seeds, were harvested from approximately 2,391 plants. Of these plants, approximately 951 were grown from seeds treated with 0.2% EMS and approximately 1,440 were grown from seeds treated with 0.4% EMS.
- the M 2 seeds from each of 50 plants were combined into one lot. This grouping resulted in a total of 48 seed lots. From late October through mid-November of the year 2000, 1000 seeds from each of 15 lots of the 0.4% EMS treatment were sown " and 700 plants of each lot were greenhouse-grown at Seaview Nursery in El Rio, CA 93060. In addition, 1,500 seeds from all of the 48 lots were sown in late • October of the year 2000, and 765 plants from each of the lots were field-grown at Semillas Pan American Chile LTDA, in Pigorgegua, Chile.
- a Hewlett Packard 1100 complete with a quaternary pump, vacuum degassing system, six-way injection valve, temperature regulated autosampler, column oven and Photodiode Array detector was used.
- the column was a Waters YMC 30, 5-micron, 4.6 x 250 mm with a guard column of the same material.
- Standards were obtained from DHI- Water & Environment, DK - 2970 Horsholm, Denmark and Sigma Chemical Co., St. Louis, MO 63178.
- the solvents for the mobile phase were 81 methanol: 4 water: 15 tetrahydrofuran stabilized with 0.2% BHT. Injections were 20 ⁇ l . Separation was isocratic at 30°C with a flow rate of 1.7 ml/minute. The peak responses were measured at 447 nm.
- samples were selected having zeaxanthin ratios greater than 10 percent, combined lutein and zeaxanthin content greater than 1.12 mg/g fresh weight and combined lutein and zeaxanthin content less than 0.24 mg/g fresh weight.
- a total of 347 mutants were identified having a sum of lutein plus zeaxanthin greater than 1.12 mg/g, and 43 mutants having a zeaxanthin ratio greater than 10 percent were identified from 8192 samples using these selection parameters.
- the total number of mutants resulting from each EMS seed treatment is shown in Table 5, below.
- mutants having a zeaxanthin ratio greater than about 10 percent zeaxanthin about 47 percent had between 10 and under 13 percent, whereas 53 percent exhibited 13 percent or greater.
- Example 5 Carotenoid Composition in Petals of Select Marigolds Carotenoid compositions were determined for 'Scarletade' wild-type and mutant samples selected from those identified in the screening procedure described in Example 2. Petal samples were stored in a -80°C freezer until mutants were identified. Samples were lyophilized, and the dried tissue was stored under argon at -80°C until ready for analysis. Extraction procedures were performed under red light. Dried petals were ground to pass through a No. 40 sieve mesh size. A ground sample was accurately weighed and transferred into a 100 ml red volumetric flask. To the sample, 500 microliters ( ⁇ l) of H2O were added, and the mixture was swirled for 1 minute .
- the shaken sample was diluted to volume (100 ml) with 10% sodium sulfate solution and shaken vigorously for one minute. The sample remained in the dark for at least 30 minutes. A 35 ml aliquot was removed from the approximately 50 ml upper phase, and transferred to a sample cup. An additional 30 ml of hexane were added into the flask that was then shaken at 160 rpm for 10 minutes. After approximately one hour, the upper phases were combined. For HPLC analysis, 10 ml aliquots were dried under nitrogen and stored under argon at -80 °C.
- the mobile phase was returned to the initial conditions and the column equilibrated for an additional 10 minutes.
- the column temperature was maintained at 27°C and the flow rate was 0.4 ml/minute. Injections were 10 ⁇ l .
- the majority of peak responses were measured at 450 nm and additional areas added from 286, 348, 400 and 472 nm extracted channels .
- Marigold mutant selection 124-257 that exhibits an increased zeaxanthin to lutein ratio compared to wild type was selfed and the resulting seed was maintained. Plants from the selfing of marigold selection 124-257 were used as male parents in a cross with female parent PanAmerican Seed proprietary breeding line F9 Ap (85368-4). From this cross, Fi plants were produced and selfed to yield an F 2 population.
- TLC thin layer chromatography
- Marigold mutant selection 100-198 was selfed and the resulting seed was maintained. Plants from the selfing of marigold selection 100-198 were used as the male parent in a cross with the female parent selection 14649-3 described above. From this cross, Fi seeds were collected, and of these 30 seeds were planted. Eleven of the resulting plants were selfed. From this cross, F 2 seeds were collected, and 400 of those seeds were planted and grown.
- TLC analysis as described above, was used to analyze leaves of 151 seedlings. Thirty-two plants were identified based on reduced epoxycarotenoid production typical of mutant selection 100-198. The remaining TLC extract was analyzed using high performance liquid chromatography (HPLC) , performed using a modified Example 5 protocol. Modifications include the following: dried samples were resuspended into methyl tert-butyl ether and methanol, all gradient conditions used water increased to 6 percent with a corresponding 1 percent decrease in methanol, and column temperature was maintained at 25°C.
- Marigold mutant selection 101-190 was selfed and the resulting seed was maintained. Marigold selection 101-190 was used as the male parent in a cross with the female parent selection 14649-3 described above. From this cross, F x seeds were collected and of those seeds, 30 were planted. Six of the resulting plants were selfed. From this latter cross, F 2 seeds were collected, planted and grown .
- Petal and leaf samples of the ten selections were extracted and analyzed according to the protocol in Example 5 with modifications noted above. The results for petals are shown in Tables 7b and 7c. In addition, non-saponified petal samples were analyzed to determine the percentage of non- esterified zeaxanthin. Those data are presented in Table 8. Table 7a
- the oleoresin is stirred for 3 hours with 100 ml of isopropanol at 20°C.
- the resulting suspension is filtered through filter paper, and the solvent is removed under vacuum at ambient temperature.
- the resulting solid is melted at 65°C and poured into a mold.
- one mixed zeaxanthin ester bar weighing 5 grams and having a mixed zeaxanthin ester content of approximately 16 wt . percent (by spectrophotometry in hexane) is obtained.
- the mixed zeaxanthin concentrate is ground into a granular state .
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002527274A CA2527274C (en) | 2003-06-03 | 2004-05-18 | Mixed zeaxanthin ester concentrate and uses thereof |
EP04752481A EP1641448A4 (en) | 2003-06-03 | 2004-05-18 | Mixed zeaxanthin ester concentrate and uses thereof |
AU2004245478A AU2004245478B9 (en) | 2003-06-03 | 2004-05-18 | Mixed zeaxanthin ester concentrate and uses thereof |
JP2006514887A JP2007525189A (en) | 2003-06-03 | 2004-05-18 | Mixed zeaxanthin ester concentrates and their uses |
MXPA05013025 MX259137B (en) | 2003-06-03 | 2004-05-18 | Mixed zeaxanthin ester concentrate and uses thereof. |
BRPI0410859-0A BRPI0410859A (en) | 2003-06-03 | 2004-05-18 | purified carotenoid concentrate, diluted purified carotenoid composition, composition suitable for oral administration, mammalian food or drink, and cream, lotion or topical ointment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/453,403 | 2003-06-03 | ||
US10/453,403 US7081478B2 (en) | 2001-06-29 | 2003-06-03 | Mixed zeaxanthin ester concentrate and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004108635A2 true WO2004108635A2 (en) | 2004-12-16 |
WO2004108635A3 WO2004108635A3 (en) | 2005-03-24 |
Family
ID=33510384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/015472 WO2004108635A2 (en) | 2003-06-03 | 2004-05-18 | Mixed zeaxanthin ester concentrate and uses thereof |
Country Status (12)
Country | Link |
---|---|
US (1) | US7081478B2 (en) |
EP (1) | EP1641448A4 (en) |
JP (1) | JP2007525189A (en) |
KR (1) | KR20060027320A (en) |
CN (1) | CN1832737A (en) |
AU (1) | AU2004245478B9 (en) |
BR (1) | BRPI0410859A (en) |
CA (1) | CA2527274C (en) |
IN (1) | IN2005DE06124A (en) |
MX (1) | MX259137B (en) |
WO (1) | WO2004108635A2 (en) |
ZA (1) | ZA200509812B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104090061A (en) * | 2014-07-30 | 2014-10-08 | 江苏省农业科学院 | Method for detecting mono-cis/bicis-isomer of zeaxanthin |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6784351B2 (en) | 2001-06-29 | 2004-08-31 | Ball Horticultural Company | Targetes erecta marigolds with altered carotenoid compositions and ratios |
US7575766B2 (en) * | 2001-06-29 | 2009-08-18 | Ball Horticultural Company | Tagetes erecta with altered carotenoid compositions and ratios |
US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
US20050158294A1 (en) | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
GB0501365D0 (en) * | 2005-01-21 | 2005-03-02 | Promar As | Compositions |
US7758884B2 (en) * | 2005-01-28 | 2010-07-20 | Kemin Industries, Inc. | Formulation for increasing the deposition of dietary carotenoids in eggs |
ITRM20050209A1 (en) * | 2005-05-02 | 2006-11-03 | Sooft Italia S R L | COMPOSITION BASED ON OLIVE OIL ENRICHED AND SUPPLEMENTED WITH LUTEIN. |
AU2006253007B2 (en) | 2005-05-31 | 2012-12-20 | Alimentary Health Ltd | Feline probiotic Bifidobacteria |
DK1880001T3 (en) | 2005-05-31 | 2011-09-12 | Iams Company | Feline probiotic lactobacilli |
JP5799299B2 (en) | 2007-02-01 | 2015-10-21 | ザ・アイムス・カンパニーThe Iams Company | Method for reducing inflammation and stress in mammals using glucose antimetabolite, avocado or avocado extract |
CN101595977B (en) * | 2008-06-02 | 2013-04-03 | 浙江医药股份有限公司新昌制药厂 | Formula food beneficial to eye health and application thereof |
US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
US8702819B2 (en) * | 2008-09-10 | 2014-04-22 | Poet Research, Inc. | Oil composition and method of recovering the same |
US9061987B2 (en) * | 2008-09-10 | 2015-06-23 | Poet Research, Inc. | Oil composition and method for producing the same |
CN101675747B (en) * | 2008-09-19 | 2012-09-05 | 内蒙古伊利实业集团股份有限公司 | Liquid diary products containing lutein ester and cryptoxanthin and production method thereof |
CN101828693B (en) | 2009-03-09 | 2013-01-02 | 浙江医药股份有限公司新昌制药厂 | Preparation method and application of low-viscosity high-fluidity carotenoid oil suspension |
US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
US20110144200A1 (en) * | 2009-12-14 | 2011-06-16 | Thomas Eidenberger | Combination of carotenoids and epi-lutein |
WO2011076869A1 (en) * | 2009-12-22 | 2011-06-30 | Aakerlund Hans-Erik | Isolated green plant material |
RU2681497C2 (en) * | 2011-10-31 | 2019-03-06 | Филип Моррис Продактс С.А. | Modulating beta-damascenone in plants |
JP2016520540A (en) | 2013-03-28 | 2016-07-14 | オムニアクティブ ヘルス テクノロジーズ リミテッド | Neuroprotective effects of carotenoids in the brain |
JP6195194B2 (en) * | 2013-12-16 | 2017-09-13 | 東海光学株式会社 | Lens evaluation method |
WO2016139607A1 (en) * | 2015-03-02 | 2016-09-09 | Omniactive Health Technologies Limited | Method for protection and improvement of liver health with meso-zeaxanthin compositions |
CN111321156B (en) * | 2018-12-14 | 2021-05-25 | 华中农业大学 | Application of OsLUT1 gene in regulation and control of rice photoprotection |
CN112557544B (en) * | 2020-12-09 | 2023-06-30 | 宁夏农林科学院枸杞科学研究所 | Detection method of carotenoid metabolites of wolfberry |
CN112924591B (en) * | 2021-01-29 | 2022-10-28 | 宁夏农产品质量标准与检测技术研究所(宁夏农产品质量监测中心) | Method for detecting beta-carotene in medlar |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6218436B1 (en) * | 1993-06-28 | 2001-04-17 | The Howard Foundation | Pharmaceutically active carotenoids |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2918370A (en) * | 1955-12-23 | 1959-12-22 | Abbott Lab | Calcium pantothenate composition |
CH552388A (en) * | 1970-07-10 | 1974-08-15 | Hoffmann La Roche | LIGHT PROTECTION AGENTS. |
US4670247A (en) * | 1983-07-05 | 1987-06-02 | Hoffman-Laroche Inc. | Process for preparing fat-soluble vitamin active beadlets |
US5043170A (en) * | 1989-02-14 | 1991-08-27 | Hoffmann-La Roche Inc. | Animal feed composition containing a vitamin D metabolite |
US5290605A (en) * | 1989-06-29 | 1994-03-01 | Niva Shapira | Sun-exposure nutritional supporting composition |
IL90794A (en) | 1989-06-29 | 1995-03-15 | Shapira Niva | Nutritional sun-exposure supporting composition |
ATE153700T1 (en) * | 1989-08-30 | 1997-06-15 | Applied Food Biotech Inc | METHOD FOR PRODUCING A COMPOSITION CONTAINING ZEAXANTHIN USING A MICROORGANISM OF THE SPECIES FLAVOBACTERIUM MULTIVORUM |
US5618988A (en) * | 1990-03-02 | 1997-04-08 | Amoco Corporation | Enhanced carotenoid accumulation in storage organs of genetically engineered plants |
US5684238A (en) * | 1990-03-02 | 1997-11-04 | Amoco Corporation | Biosynthesis of zeaxanthin and glycosylated zeaxanthin in genetically engineered hosts |
GB9105420D0 (en) | 1991-03-14 | 1991-05-01 | Ici Plc | Expression of genes in transgenic plants |
US5270063A (en) * | 1992-08-03 | 1993-12-14 | Kellogg Company | Ready-to-eat cereal products enriched with beta-carotene |
US5258189A (en) * | 1992-08-28 | 1993-11-02 | General Mills, Inc. | Method for making vitamin enriched cereal |
ES2147762T3 (en) * | 1993-06-24 | 2000-10-01 | Hoffmann La Roche | CAROTENOID PIGMENTATION. |
US6329432B2 (en) * | 1993-06-28 | 2001-12-11 | The Howard Foundation | Mesozeaxanthin formulations for treatment of retinal disorders |
CH685189A5 (en) * | 1993-11-19 | 1995-04-28 | Marigen Sa | Ultramicroemulsions spontaneously dispersible concentrates with antitumoral effective xanthophyll esters. |
AU702584B2 (en) * | 1993-12-27 | 1999-02-25 | Kirin Holdings Kabushiki Kaisha | DNA strands useful for the synthesis of xanthophylls and the process for producing the xanthophylls |
US5382714A (en) * | 1994-03-17 | 1995-01-17 | The Catholic University Of America | Process for isolation, purification, and recrystallization of lutein from saponified marigold oleoresin and uses thereof |
US5523494A (en) * | 1994-07-20 | 1996-06-04 | Industrial Organica, S.A. De C.V. | Process for the isomerization of lutein |
ATE218162T1 (en) * | 1994-08-23 | 2002-06-15 | Kirin Brewery | KETO GROUP INTRODUCING ENZYME, DNA CODING THEREOF AND METHOD FOR PRODUCING KETOCAROTENOID |
DE69511515T2 (en) * | 1994-12-21 | 2000-01-20 | Hoffmann La Roche | Carotenoid ketones and esters |
US5935624A (en) * | 1995-02-06 | 1999-08-10 | Wisconsin Alumni Research Foundation | Low phosphorus animal feed containing 1α-hydroxylated vitamin D compounds and method of preparing |
AU719671B2 (en) | 1995-06-07 | 2000-05-18 | Howard Foundation, The | Pharmaceutically active carotenoids |
US5695794A (en) * | 1995-08-10 | 1997-12-09 | Amoco Corporation | Use of 25-hydroxycholecalciferol in a dietary supplement process for ameliorating the effects of tibial dyschondroplasia in poultry while maintaining weight gain |
US5747544A (en) * | 1995-10-31 | 1998-05-05 | Applied Food Biotechnology, Inc. | Method of using pure 3R-3'R stereoisomer of zeaxanthin to treat or prevent retinal degeneration in humans |
US5827652A (en) * | 1995-10-31 | 1998-10-27 | Applied Food Biotechnology, Inc. | Zeaxanthin formulations for human ingestion |
US5854015A (en) * | 1995-10-31 | 1998-12-29 | Applied Food Biotechnology, Inc. | Method of making pure 3R-3'R stereoisomer of zeaxanthin for human ingestion |
US5916791A (en) * | 1995-11-24 | 1999-06-29 | Hirschberg; Joseph | Polynucleotide molecule from Haematococcus pluvialis encoding a polypeptide having a β--C--4--oxygenase activity for biotechnological production of (3S,3S)astaxanthin |
US5648564A (en) * | 1995-12-21 | 1997-07-15 | Kemin Industries, Inc. | Process for the formation, isolation and purification of comestible xanthophyll crystals from plants |
FR2749758B1 (en) * | 1996-06-12 | 1998-08-07 | Oenobiol Sa Lab | COMPOSITION WITH TANNING AND PHOTOPROCTOR ACTIVITY AND ITS AESTHETIC APPLICATIONS |
US5858700A (en) * | 1997-04-03 | 1999-01-12 | Kemin Foods, Lc | Process for the isolation and purification of lycopene crystals |
US5959138A (en) * | 1997-11-25 | 1999-09-28 | Industrial Organica S.A. De C.V. | Short chain diesters and process for making the same |
US6191293B1 (en) * | 1998-04-20 | 2001-02-20 | Inexa, Industria Extractora C.A. | Trans-xanthophyll ester concentrates of enhanced purity and methods of making same |
JP2002516117A (en) | 1998-05-22 | 2002-06-04 | ユニバーシティ オブ メリーランド | Carotenoid ketolase gene and gene product, production of ketocarotenoids, and method of modifying carotenoids using the gene |
US6224876B1 (en) * | 1998-08-04 | 2001-05-01 | Biyani Milind Kesharlal | Isolation and formulations of nutrient-rich carotenoids |
US6056962A (en) * | 1998-08-04 | 2000-05-02 | Kesharlal; Biyani Milind | Isolation and formulations of nutrient-rich carotenoids |
US5955102A (en) * | 1998-09-04 | 1999-09-21 | Amway Corporation | Softgel capsule containing DHA and antioxidants |
IL126076A (en) | 1998-09-04 | 2005-05-17 | Ibr Ltd | Transparent composition comprising phytoene and phytofluene |
NL1010351C2 (en) * | 1998-10-19 | 2001-01-08 | Werklust & Beheer B V | Carotenoid esters for use in the prevention and treatment of eye diseases. |
US6262284B1 (en) * | 1998-10-21 | 2001-07-17 | University Of Maryland | Process for extraction and purification of lutein, zeaxanthin and rare carotenoids from marigold flowers and plants |
US6232530B1 (en) | 1998-11-30 | 2001-05-15 | University Of Nevada | Marigold DNA encoding beta-cyclase |
US6254898B1 (en) * | 2000-05-25 | 2001-07-03 | Protective Factors, Inc. | Nutraceutical composition for protection against solar radiation |
US7575766B2 (en) * | 2001-06-29 | 2009-08-18 | Ball Horticultural Company | Tagetes erecta with altered carotenoid compositions and ratios |
US6784351B2 (en) * | 2001-06-29 | 2004-08-31 | Ball Horticultural Company | Targetes erecta marigolds with altered carotenoid compositions and ratios |
US8088363B2 (en) * | 2002-10-28 | 2012-01-03 | Zeavision Llc | Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin |
-
2003
- 2003-06-03 US US10/453,403 patent/US7081478B2/en not_active Expired - Lifetime
-
2004
- 2004-05-18 KR KR1020057023238A patent/KR20060027320A/en not_active Application Discontinuation
- 2004-05-18 MX MXPA05013025 patent/MX259137B/en active IP Right Grant
- 2004-05-18 CN CNA200480021539XA patent/CN1832737A/en active Pending
- 2004-05-18 EP EP04752481A patent/EP1641448A4/en not_active Withdrawn
- 2004-05-18 WO PCT/US2004/015472 patent/WO2004108635A2/en active Application Filing
- 2004-05-18 AU AU2004245478A patent/AU2004245478B9/en not_active Ceased
- 2004-05-18 JP JP2006514887A patent/JP2007525189A/en active Pending
- 2004-05-18 CA CA002527274A patent/CA2527274C/en active Active
- 2004-05-18 BR BRPI0410859-0A patent/BRPI0410859A/en not_active IP Right Cessation
-
2005
- 2005-12-02 ZA ZA200509812A patent/ZA200509812B/en unknown
- 2005-12-28 IN IN6124DE2005 patent/IN2005DE06124A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6218436B1 (en) * | 1993-06-28 | 2001-04-17 | The Howard Foundation | Pharmaceutically active carotenoids |
Non-Patent Citations (1)
Title |
---|
See also references of EP1641448A2 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104090061A (en) * | 2014-07-30 | 2014-10-08 | 江苏省农业科学院 | Method for detecting mono-cis/bicis-isomer of zeaxanthin |
CN104090061B (en) * | 2014-07-30 | 2015-11-25 | 江苏省农业科学院 | The detection method of zeaxanthin list cis, two cis-isomer |
Also Published As
Publication number | Publication date |
---|---|
KR20060027320A (en) | 2006-03-27 |
BRPI0410859A (en) | 2006-07-04 |
IN2005DE06124A (en) | 2007-11-30 |
AU2004245478A1 (en) | 2004-12-16 |
MX259137B (en) | 2008-07-29 |
JP2007525189A (en) | 2007-09-06 |
WO2004108635A3 (en) | 2005-03-24 |
US7081478B2 (en) | 2006-07-25 |
EP1641448A4 (en) | 2007-01-31 |
ZA200509812B (en) | 2006-12-27 |
US20040022881A1 (en) | 2004-02-05 |
CN1832737A (en) | 2006-09-13 |
CA2527274A1 (en) | 2004-12-16 |
EP1641448A2 (en) | 2006-04-05 |
AU2004245478B9 (en) | 2008-10-16 |
AU2004245478B2 (en) | 2008-06-05 |
MXPA05013025A (en) | 2007-01-26 |
CA2527274C (en) | 2009-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2527274C (en) | Mixed zeaxanthin ester concentrate and uses thereof | |
AU2002320200B2 (en) | Tagetes erecta marigolds with altered carotenoid compositions and ratios | |
AU2002320200A1 (en) | Tagetes erecta marigolds with altered carotenoid compositions and ratios | |
US10721946B2 (en) | Capsicum variety exhibiting a hyper-accumulation of zeaxanthin and products derived therefrom | |
US20120216321A1 (en) | Capsicum variety exhibiting a hyper-accumulation of zeaxanthin and products derived therefrom | |
US20060265784A1 (en) | Tagetes erecta MARIGOLDS WITH ALTERED CAROTENOID COMPOSITIONS AND RATIOS | |
MX2007009710A (en) | A capsicum variety exhibiting a hyper-accumulation of zeaxanthin and products derived therefrom. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480021539.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2527274 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004245478 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/09812 Country of ref document: ZA Ref document number: PA/a/2005/013025 Country of ref document: MX Ref document number: 200509812 Country of ref document: ZA Ref document number: 1020057023238 Country of ref document: KR Ref document number: 2006514887 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2004245478 Country of ref document: AU Date of ref document: 20040518 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004245478 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6124/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004752481 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057023238 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004752481 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0410859 Country of ref document: BR |